ArticleInternational journal of geriatric psychiatry2015
Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis.
Article in International journal of geriatric psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis.European journal of nuclear medicine and molecular imaging · 2020Pooled it
- Nuclear Medicine Imaging Biomarkers in Parkinson's Disease: Past, Present, and Future Directions.Medical sciences (Basel, Switzerland) · 2025Review
- [PCN reports : psychiatry and clinical neurosciences · 2025Article
- The Usefulness of 131 I-MIBG Myocardial Scintigraphy in a Case of Pure Autonomic Failure - First Report in the Literature.Annals of Indian Academy of Neurology · 2025Article
- Correlation analyses between MIBG myocardial scintigraphy and monoamine levels in dementia with Lewy bodies show potential link with the serotonergic system.Clinical parkinsonism & related disorders · 2025Article
- Atypical Parkinsonian Syndromes: Structural, Functional, and Molecular Imaging Features.AJNR. American journal of neuroradiology · 2024Review
- Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine.Theranostics · 2024Review
- Optimal Protocol and Clinical Usefulness ofNuclear medicine and molecular imaging · 2023Article
- Phantom-Based Standardization Method forAnnals of nuclear cardiology · 2023Article
- The Noradrenergic System in Parkinson's Disease.Frontiers in pharmacology · 2020Review
- Dementia with Lewy bodies - from scientific knowledge to clinical insights.Nature reviews. Neurology · 2019Review
- Imaging the Autonomic Nervous System in Parkinson's Disease.Current neurology and neuroscience reports · 2018Review
- The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions.Current neurology and neuroscience reports · 2018Review
- Optimizing Parkinson's disease diagnosis: the role of a dual nuclear imaging algorithm.NPJ Parkinson's disease · 2018Review
- Imaging Parkinson's disease below the neck.NPJ Parkinson's disease · 2017Article
- Imaging Systemic Dysfunction in Parkinson's Disease.Current neurology and neuroscience reports · 2016Review
- (123)I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review.Journal of movement disorders · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIodine-123 metaiodobenzylguanidine (MIBG) cardiac scintigraphy has shown the potential to discriminate dementia with Lewy bodies (DLB) from Alzheimer's disease (AD). However, these studies did not reflect clinical practice, as patients with ischemic heart disease, heart failure, diabetes mellitus, arterial hypertension, and hyperlipidemia and patients treated with antidepressants like trazodone were excluded.
methodsThis study aimed to evaluate the use of MIBG cardiac scintigraphy to diagnose DLB in clinical practice. Moreover, the potential diagnostic value of MIBG cardiac scintigraphy in patients with clinically ambiguous dementia diagnosis (DLB versus AD) was tested. Eighty-five patients with a possible clinical diagnosis of DLB entered the study. MIBG uptake was determined by calculating the heart-to-mediastinum-uptake ratio (H/M).
resultsThe average H/M ratio was 1.42 ± 0.35. The number of core features for DLB and the H/M ratio were negatively correlated (p = 0.001; r = -0.360). With an H/M ratio cutoff of 1.68 in 20 patients with clinically ambiguous dementia diagnoses (DLB versus AD) at the moment of MIBG cardiac scintigraphy, 95% (19/20) of the patients were correctly classified as compared with clinical or definite diagnosis at follow-up, with sensitivity and specificity values for diagnosing DLB of 100% (16/16) and 75% (3/4), respectively. The H/M ratio was influenced only by age (p = 0.046; r = -0.217) and gender (p = 0.024) and not by any other variable studied.
conclusionsThe MIBG cardiac scintigraphy H/M ratio is a possible diagnostic biomarker for DLB in routine clinical practice and might have an added diagnostic value in case of doubt between DLB and AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.